Who is sponsoring NCT05598775?

NCT05598775 is sponsored by ReNeuron Limited.

What drugs are being tested in NCT05598775?

Interventions in NCT05598775: Non Interventional long term safety follow up.

What condition does NCT05598775 study?

NCT05598775 studies Ischemic Stroke.

Is NCT05598775 still recruiting?

NCT05598775 is currently enrolling by invitation. Last updated 31 March 2023.

Last reviewed 2023-03-31 · How we verify

NCT05598775: LTFU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-Term Safety Study of CTX0E03 in Subjects Who Completed PISCES III Study

ENROLLING BY INVITATION Last updated 31 March 2023

What this trial tests

trial testing Non Interventional long term safety follow up in Ischemic Stroke in 9 participants. Enrolling by invitation.

Timeline

1 November 2022

Primary endpoint
1 November 2026

31 December 2026

Quick facts

Lead sponsor	ReNeuron Limited
Status	ENROLLING BY INVITATION
Study type	OBSERVATIONAL
Enrollment	9
Start date	1 November 2022
Primary completion	1 November 2026
Estimated completion	31 December 2026
Sites	1 location across United States

Drugs / interventions tested

Non Interventional long term safety follow up

Conditions studied

Ischemic Stroke — all drugs for Ischemic Stroke →

Sponsor

ReNeuron Limited — full company profile →

Who can join

Adults 35 to 75, any sex, with Ischemic Stroke. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this long-term safety study is to follow up subjects treated with CTX0E03 DP to monitor for delayed oncological, neurological, and CTX0E03 DP-related adverse events and to monitor survival

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cell therapy for stroke and spinal cord injury in clinical trials.
Fan Y, Wong ST, Goh ELK, Chan JKY. · · 2026 · PMID 41641797 · DOI 10.1093/stcltm/szaf082

Verify or expand the search:

Other recruiting trials for Ischemic Stroke

Currently open trials in the same condition.

NCT07509645 — Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Post · Phase 3 · recruiting
NCT07375953 — Repeated Intravenous Thrombolysis for Ischemic Stroke Within 3.0 Hours of Onset With Tenecteplase (RITIS-TNK) · Phase 2 · recruiting
NCT07375966 — Repeated Intravenous Thrombolysis for Ischemic Stroke With Medium to Large Vessel Occlusion Presenting Within 4.5 Hours · Phase 2 · recruiting
NCT07491952 — Continuous Dual Aspiration Technique With Zoom System for Stroke · recruiting
NCT07371455 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LWP779 in Healthy Participants · Phase 1 · recruiting

Other ReNeuron Limited trials

Trials by the same sponsor.

NCT03629275 — Investigation of Neural Stem Cells in Ischemic Stroke · Phase 2 · terminated
NCT03333980 — An Ischaemic Stroke Observational Study · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05598775 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ReNeuron Limited
Last refreshed: 31 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05598775.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing